AstraZeneca Oncology Head Defends China Deals Amid Looming Investment Curbs
AstraZeneca’s oncology head said drugmakers should be able to seek promising medicines globally as plans to curb U.S.-China biotech investment loom.
Related stories
Suzhou Denglin Technology: dealings in H shares on stock exchange expected to start Nov. 10
L impact | EQUITY | Oct 29, 2026, 10:06 PM UTC
Suzhou Denglin Technology Co: global offering 6.1 million H shares
L impact | EQUITY | Oct 29, 2026, 10:06 PM UTC
Walmart and Symbotic Expand Commercial Agreement
Walmart and Symbotic expanded their commercial agreement to support supply chain transformation.
M impact | EQUITY | Oct 29, 2026, 10:04 PM UTC
Amazon Shares Drop 7% After Capital Spending Exceeds Expectations
Amazon shares fell about 7% after hours Thursday after third-quarter capital expenditures heavily outpaced Wall Street projections. The report also noted cooler e-commerce growth.
M impact | EQUITY | Oct 29, 2026, 10:04 PM UTC
Edison International Reports Q3 Adjusted EPS of $1.92
Edison International reported third-quarter revenue of $4.89 billion, below the $5.34 billion analyst estimate. It reaffirmed 2026 core EPS guidance of $5.90 to $6.20 and outlined
M impact | EQUITY | Oct 29, 2026, 10:04 PM UTC
GoDaddy Sets Full-Year 2026 Revenue Outlook at $5.22B–$5.26B
GoDaddy expects 2026 revenue of $5.22 billion to $5.26 billion, versus FactSet consensus of $5.24 billion.
M impact | EQUITY | Oct 29, 2026, 10:03 PM UTC